The historical rank and industry rank for Seres Therapeutics's Net Margin % or its related term are showing as below:
MCRB'
s Net Margin % Range Over the Past 10 Years
Min: -3509.5 Med: -273.39 Max: -45.25
Current: -90.03
MCRB's Net Margin % is ranked better than 56.17% of 1029
companies
in the Biotechnology industry
Industry Median: -157.22
vs MCRB: -90.03
Seres Therapeutics Net Margin % Historical Data
The historical data trend for Seres Therapeutics's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Seres Therapeutics's Net Margin %
For the Biotechnology subindustry, Seres Therapeutics's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Seres Therapeutics's Net Margin % Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Seres Therapeutics's Net Margin % distribution charts can be found below:
* The bar in red indicates where Seres Therapeutics's Net Margin % falls into.
Seres Therapeutics Net Margin % Calculation
Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.
Seres Therapeutics's Net Margin for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Seres Therapeutics (NAS:MCRB) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Seres Therapeutics Net Margin % Related Terms
Thank you for viewing the detailed overview of Seres Therapeutics's Net Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.
Seres Therapeutics (Seres Therapeutics) Business Description
Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
MCRB has been successfully added to your 